Annacarolina da Silva

Assistant Professor of Pathology and Laboratory Medicine

Weill Cornell Medical College
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Annacarolina da Silva is an Assistant Professor of Pathology and Laboratory Medicine at Weill Cornell Medical College, USA. Her research focuses on the mechanisms of cancer, specifically in areas such as pancreatic ductal adenocarcinoma and colorectal carcinoma. Recent publications include studies on leukocyte heterogeneity in pancreatic cancer and the association of Fusobacterium nucleatum with T-cell subsets in colorectal cancer. Additionally, she has contributed to the understanding of morphologic features in mucinous ovarian tumors and the clinical implications of insulin-like growth factor-1 receptor expression in cancer outcomes.

Articles (6)

Purpose: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. Experimental Design: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Results: Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the mitogen activated kinase (MAPK) pathway, including BRAF mutations and in-frame deletions and receptor-tyrosine kinase (RTK) fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers such as GNAS, MYC, PIK3CA and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid (PDO) models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (Median Age: 62.6 vs. 65.7 years , p = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. Conclusions: This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.

Year:

2024

Purpose: Approximately 8-10% of pancreatic ductal adenocarcinomas (PDAC) do not harbor mutations in KRAS. Understanding the unique molecular and clinical features of this subset of pancreatic cancer is important to guide patient stratification for clinical trials of molecularly targeted agents. Experimental Design: We analyzed a single-institution cohort of 795 exocrine pancreatic cancer cases (including 785 PDAC cases) with a targeted multi-gene sequencing panel and identified 73 patients (9.2%) with KRAS wild-type (WT) pancreatic cancer. Results: Overall, 43.8% (32/73) of KRAS WT cases had evidence of an alternative driver of the mitogen activated kinase (MAPK) pathway, including BRAF mutations and in-frame deletions and receptor-tyrosine kinase (RTK) fusions. Conversely, 56.2% of cases did not harbor a clear MAPK driver alteration, but 29.3% of these MAPK-negative KRAS WT cases (12/41) demonstrated activating alterations in other oncogenic drivers such as GNAS, MYC, PIK3CA and CTNNB1. We demonstrate potent efficacy of pan-RAF and MEK inhibition in patient-derived organoid (PDO) models carrying BRAF in-frame deletions. Moreover, we demonstrate durable clinical benefit of targeted therapy in a patient harboring a KRAS WT tumor with a ROS1fusion. Clinically, patients with KRAS WT tumors were significantly younger in age of onset (Median Age: 62.6 vs. 65.7 years , p = 0.037). SMAD4 mutations were associated with a particularly poor prognosis in KRAS WT cases. Conclusions: This study defines the genomic underpinnings of KRAS WT pancreatic cancer and highlights potential therapeutic avenues for future investigation in molecularly directed clinical trials.

Year:

2024

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (9)

Hersh Gupta

Dana-Farber Cancer Institute

UNITED STATES
View details

Kimmie Ng

Associate Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute

UNITED STATES
View details

Andrew D Cherniack

Group Leader

Dana-Farber Cancer Institute

UNITED STATES
View details

Jeffrey Clark

Associate Professor

Harvard University

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Elizabeth Cohen

Dana-Farber Cancer Institute

UNITED STATES
View details

Chen Yuan

Assistant Professor

Cedars-Sinai Medical Center

UNITED STATES
View details

Michael Rosenthal

Brigham and Women's Hospital

UNITED STATES
View details

Matthew Meyerson

Director, Center for Cancer Genomics

Dana-Farber Cancer Institute

UNITED STATES
View details